Press releases

Release issued 29th December 2003

Embil Pharmaceutical Co. Ltd. has announced today, that successful results of two clinical trials demonstrating the safety and effectiveness of its novel triple-active topical antivaginitis products (Neo-Penotran® Forte and Neo- Penotran® Forte-L) have been accepted for presentation at the World Conference on Vaginitis to be held in Costa Rica between the dates of 10-13 January 2004. "The study results further demonstrate the high clinical success of the once-daily FORTE version of our established and world-wide selling triple active vaginal product Neo- Penotran®. The development of Neo-Penotran® Forte and Neo-Penotran® Forte-L has the added benefits of better patient compliance and ease of usage with once daily dosing" said Dr. Koral Embil, Vice President, Head of R&D and Business Development of Embil Pharmaceutical Co. Ltd. "These products are not only more convenient for use with once-daily dosing, but may provide additional advantages such as rapid management of vulvo-vaginal pain, irritation and discomfort experienced by women suffering from vaginitis, contributing to better patient compliance. The study results have shown that the once-daily FORTE version of Neo- Penotran® provide even higher clinical and microbiological succes rates than the twice-daily version in all three major types of vaginitis and mixed vaginal infections with an excellent safety profile". The titles of the two clinical studies to be presented are as follows: 1. Efficacy of Once Daily, 7-day Treatment with Neo- Penotran® Forte - A Triple-active Pessary for the Treatment of Single and Mixed Vaginal Infections. 2. Absorption and Tolerability of Neo- Penotran® Forte-L and Neo-Penotran® Forte Pessaries in Healthy Volunteers. A significant number of clinical trials have been carried out with Neo-Penotran® , Neo- Penotran® Forte and Neo- Penotran® Forte-L worldwide. Results of these studies have been presented at various meetings and a number of publications have appeared in distinguished journals. Comparative clinical trials are being prepared for publication. Patents for Neo-Penotran® Forte-L have been applied for (Anti-Vaginitis composition for topical use comprising one or more anti-vaginitis medicaments and one or more local anaesthetics. PCT/GB97/01355).

Each dose of Neo-Penotran® Forte contains 750 mg metronidazole and 200 mg miconazole nitrate providing therapeutic concentrations for the local treatment of the three main types of vaginal infections and mixed forms of vaginitis. The dose is applied once daily for a 7 day treatment Each dose of Neo-Penotran® Forte-L contains 750 mg metronidazole and 200 mg miconazole nitrate plus 100 mg lidocaine. The dose is applied once daily for a 7 day treatment. The presence of lidocaine serves to reduce pain caused by irritation and inflammation due to vaginitis, sometimes more acute during the first 3 days of treatment. Both ingredients, metronidazole and miconazole nitrate, have been established as first line treatment of vaginal candidiasis, bacterial and trichomonal vaginitis.

Because Neo-Penotran® cointains both these ingredients, it is of clear value in the treatment of vaginitis due to any or all of the three common types of vaginitis, Neo-Penotran® is of special value for the immediate treatment of mixed forms of vaginitis.

(17th November 2004) Sulidin® 1% Nimesulide LPS® gel receives European and US Patents

(7th November 2004) New Clinical Study results on SULIDIN® 1% Nimesulide LPS gel presented at the 8'th World Congress on Clinical Pharamacology and Therapeutics, Brisbane, Australia, 1-6 August 2004.

(6th June 2003) Australian Patent Approval announced for SULIDIN LPS (Topical Nimesulide Gel) formulation.

(10th October 2002) Recent Patent Approvals for SULIDIN® LPS® (Topical Nimesulide Gel)

(9th October 2002) Two New Clinical study reports released for Kortos® HC Cream used in the treatment of benign anorectal diseases.